These data and those of others has demonstrated that KRAS mutations occur more frequently in ICC than those in NRAS (9), therefore we prioritized validating loss-of-function mutations that genetically interact with KRASG12D. This evidence concerns the gene KRAS and intrahepatic cholangiocarcinoma.